A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients
| Autor: | Sabahattin Kaymakoglu, Mehmet Bektas, Emel Ahishali, Binnur Pinarbasi, Hakan Bozkaya, F. Oğuz Önder, Cihan Yurdaydin, Yilmaz Cakaloglu, A. Mithat Bozdayi, Selim Badur, Atilla Ökten, Ramazan Idilman, Kubilay Cinar, Selim Karayalcin |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Hepatitis B virus viruses Mutation Missense Organophosphonates Pharmacology medicine.disease_cause Gastroenterology Antiviral Agents Pharmacotherapy Hepatitis B Chronic Virology Internal medicine Drug Resistance Viral medicine BDNA test Adefovir Humans Hepatitis B e Antigens Seroconversion Salvage Therapy Hepatology business.industry Adenine virus diseases Lamivudine Sequence Analysis DNA Hepatitis B Middle Aged Viral Load medicine.disease Infectious Diseases Treatment Outcome Amino Acid Substitution DNA Viral Female business Viral load medicine.drug |
| Zdroj: | Journal of viral hepatitis. 16(4) |
| ISSN: | 1365-2893 |
| Popis: | SUMMARY. The aims of the study were to investigate the efficacy of rescue therapy with lamivudine (LAM) and adefovir (ADV) combination for 6 months followed by ADV monotherapy in lamivudine-resistant chronic hepatitis B (LAM-R CHB) patients, and to analyze the frequency of ADV resistance mutant development in such patients. A total of 170 consecutive LAM-R CHB patients (male/female: 130/ 40, mean age: 42.9 ± 13.4 years) with viral breakthrough under LAM therapy were analyzed. A total of 68 had HBeAg-positive. Patients received rescue therapy with LAM [100 mg (qd)]+ADV [10 mg (qd)] for 6 months after which LAM was discontinued. HBV-DNA was assessed with the HBV-DNA 3.0 bDNA assay. ADV-resistant mutations were identified by sequencing the reverse transcriptase region. The median duration of rescue therapy was 24 months. Cumulative probability of becoming HBV-DNA undetectable was 33.8%, 59.6% and 68.2% after 24, 48 and 96 weeks of treatment, respectively. These figures were 43.2%, 58.0% and 73.1% for ALT normalization. Among 68 HBeAg-positive CHB patients, 10 patients had an e-antigen seroconversion. Low baseline HBV-DNA level ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|